Exscientia
AI drug discovery platform merging huge datasets with automated labs
Exscientia's merger with Recursion creates a formidable data and compute engine for early-stage discovery, but its pipeline remains preclinical or early-phase. Bet on the platform, not yet on approved drugs. For validated clinical candidates, look at Schrödinger or Relay Therapeutics.
Verified 18d ago · liveness 60/100 · cite: rightaichoice.com/tools/exscientia
- Pharma companies accelerating early-stage drug discovery
- Oncology and rare disease drug development programs
- Partnerships needing access to large-scale biological datasets
- Organizations seeking to reduce clinical trial failure rates
- Companies needing a fully validated late-stage clinical pipeline
- Small biotechs without resources to integrate complex AI platforms
- Therapeutic areas outside oncology and rare diseases
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Exscientia if you need a drug discovery platform with validated late-stage clinical assets or if you are a small biotech seeking an off-the-shelf AI tool without a partnership commitment.
No public pricing; requires direct negotiations and likely minimum contract commitments.
Exscientia's pricing is enterprise-only, with no published tiers. It is most suitable for large pharma partners with multi-year discovery budgets. Compared to Schrödinger (which offers software licenses starting around $20K/year) or Relay Therapeutics (also partnership-focused), Exscientia likely commands higher upfront commitments due to its wet-lab and compute infrastructure.
In short
Exscientia — AI drug discovery platform merging huge datasets with automated labs. Best for Pharma companies accelerating early-stage drug discovery, Oncology and rare disease drug development programs, Partnerships needing access to large-scale biological datasets. Contact Sales pricing.
Viability Score
How likely is Exscientia to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- Phenomics cell imaging and analysis
- Transcriptomics data integration
- Proteomics data integration
- ADME screening and prediction
- De-identified patient data integration
- Automated wet lab with robotics and computer vision
- Machine learning for target identification
- AI-driven molecule design and optimization
- BioHive-2 NVIDIA-powered supercomputer
- End-to-end Recursion OS platform
- First-in-class and best-in-class medicine pipeline
- Preclinical to IND-enabling study acceleration
- Proprietary dataset >50 petabytes
- Multi-omic data integration
About Exscientia
Exscientia, now part of Recursion, is an AI-driven drug discovery platform that leverages the Recursion OS—combining one of the world's largest proprietary biological and chemical datasets (>50 petabytes) with automated wet labs and machine learning—to identify novel targets and design optimized molecules. The platform aims to reduce the 90% failure rate of traditional drug discovery by enabling faster, more efficient hit identification through IND-enabling studies. Key features include phenomics cell imaging, transcriptomics, proteomics, ADME data, de-identified patient data, and a continuously improving feedback loop powered by BioHive-2, biopharma's most powerful supercomputer built with NVIDIA. Its pipeline spans oncology (advanced solid tumors, lymphomas, B-cell malignancies) and rare diseases (familial adenomatous polyposis, hypophosphatasia). Compared to other AI drug discovery tools, Exscientia offers an end-to-end, data-rich platform with a strong focus on proprietary dataset generation and wet-lab integration, though its clinical validation is still emerging.
Behind the Verdict
Exscientia's merger with Recursion pairs one of the deepest proprietary biological datasets (>50 petabytes) with biopharma's most powerful supercomputer, BioHive-2. The platform's automated wet lab can run millions of cell experiments per week, feeding a continuous loop that improves target identification and molecule design. This is a serious bet for pharma companies looking to de-risk early-stage discovery. But the pipeline remains early: most programs are in preclinical or Phase 1/2, with no approved drugs yet. That's on par for the AI-drug-discovery field, but buyers expecting near-term clinical validation should look at Schrödinger (computational chemistry) or Relay Therapeutics (dynamic simulation). Exscientia's partnership model (Sanofi, Roche, Bayer) suggests it's best suited for large pharma with collaborative appetite, not small biotechs without integration resources. Also, the combined entity still trades as Recursion, so brand continuity may confuse. Bottom line: Exscientia/Recursion is one of the most technologically ambitious platforms in TechBio, but its value proposition is platform potential, not proven pipeline.
Researching Exscientia? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Exscientia actually fits — and what changes day-one when you adopt it.
You want to identify a novel target for a solid tumor indication. Exscientia analyzes your patient data alongside its proprietary multi-omics dataset to prioritize targets, then designs lead candidates tested in automated wet labs within months.
Outcome: A validated target and optimized lead molecule ready for IND-enabling studies, reducing typical discovery timeline by 12-18 months.
Your team lacks internal AI capabilities. Exscientia's platform screens compounds against hypophosphatasia cellular models using phenomics imaging, identifying repurposing opportunities.
Outcome: A list of top candidate molecules with efficacy data, de-risking preclinical development.
Use Cases
- Identify novel drug targets by analyzing multi-omics patient data and cellular imaging.
- Design optimized small molecules using generative AI models trained on proprietary compound data.
- Accelerate preclinical development from hit identification to IND-enabling studies using automated wet-lab feedback.
- Develop precision oncology therapies for solid tumors and lymphomas through AI-driven biomarker discovery.
- Partner with pharma companies to co-develop drugs in therapeutic areas like oncology and rare diseases.
Models Under the Hood
as of 2026-07-14
Limitations
- Pricing and access require direct business contact; no self-service tiers.
- The platform is designed for enterprise partnerships, not individual researchers.
- Reliance on proprietary data may limit external transparency.
- Pipeline is early-stage with no approved drugs yet.
as of 2026-06-25
Where the pricing makes sense
The company stage and team size where Exscientia's pricing actually pencils out — and where peers do it cheaper.
Exscientia's pricing is enterprise-only, with no published tiers. It is most suitable for large pharma partners with multi-year discovery budgets. Compared to Schrödinger (which offers software licenses starting around $20K/year) or Relay Therapeutics (also partnership-focused), Exscientia likely commands higher upfront commitments due to its wet-lab and compute infrastructure.
Setup time & first value
How long it actually takes to get something useful out of Exscientia — broken out by persona, not the marketing-page minute.
For new pharma partners: initial data sharing and platform integration takes approximately 3-6 months to customize datasets and wet-lab workflows. First target identification results typically appear within 6-9 months of project start.
Switching to or from Exscientia
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From traditional in-house discovery: Exscientia's team works with yours to integrate proprietary datasets and define target criteria. Onboarding involves data mapping and validation.
- →From competitor AI platform: Exscientia can ingest phenotypic and genomic data from other platforms, though proprietary assays may need re-running.
- →From contract research organization (CRO): Exscientia replaces stepwise CRO workflows with an end-to-end platform, reducing handoff delays.
- ↗To insourced discovery: You can export compound data and assay results; but proprietary models and datasets remain with Exscientia.
- ↗To an alternative AI platform like Schrödinger: Molecular structures and activity data are transferable; phenotypic data may not be directly comparable.
Integrations
Resources & Guides
Official links
Tools that pair well with Exscientia
Common stack mates teams adopt alongside Exscientia, with the specific reason each pairing earns its keep.
Alternatives to Exscientia
View all
Recursion
AI-driven drug discovery platform using phenomics and massive biological datasets
Nimbus Therapeutics
AI-driven small molecule drug discovery for selective oncology and immunology
Frequently Asked Questions
Categories
Used Exscientia? Help shape our editorial sentiment research.